Table 1.
The impact of classified oncomiR on the carcinogenic signature through the specific target.
| miRNA | Disease | Manipulating Mechanism | Candidate | Physiological Influence | Reference |
|---|---|---|---|---|---|
| miR-17 | LC; Ovarian cancer | CNVs; Transcriptional control (MYC) | E2F1, PTEN | Cell Growth, apoptosis, metastasis | [55,128] |
| miR-125b | LC | Epigenetic control | p53 | Apoptosis | [60] |
| miR-504 | LC | Transcriptional control (EGFR signaling) | p53 | Apoptosis | [61] |
| miR-10b | LC | Epigenetic control | Homeobox D10, | Metastasis | [71,72] |
| miR-183 | BC | Transcriptional control (ZEB1, HSF2) | PCD4, EGR1, p21, p27 | Apoptosis, DNA repair, metabolism, EMT | [84,85,86] |
| miR-96 | BC | miRNA sponge | FOXO1, PTPN9 | Proliferation, migration, metabolism | [87] |
| miR-182 | BC | miRNA sponge | FOXO1 | Metabolism | [88] |
| miR-221/222 | BC | Epigenetic control, miRNA sponge, transcriptional control (TGF-β) | Transcriptional Repressor GATA Binding 1, Adiponectin Receptor 1, Suppressor of Cytokine Signaling 1, Cyclin Dependent Kinase Inhibitor 1B, ERα, p27, and TIMP Metallopeptidase Inhibitor 3 | Proliferation, EMT process, metastasis | [89] |
| miR-23/27/24 | BC | Transcriptional control (HIC1) | Hypermethylated in Cancer 1 (HIC1), Sprouty RTK Signaling Antagonist 2, BCL2 Antagonist/Killer, PPARγ, Nischarin, Transmembrane Protein 170B, PAK2 |
Cell growth, migration | [88,99,100] |
| miR-21 | HCC; Cervical Cancer | miRNA sponge | PTEN, MMP2, MMP9, PDCD4, PTEN, TIMP-3, TNF-α, ANXA1 | Metastasis and proliferation | [105,130,131,132] |
| miR-221 | HCC | Transcriptional control (NF-κB) | CDKN1B/p27, CDKN1C/p57 DNA damage-inducible transcript 4, BMF | Cell growth, apoptosis | [108,109] |
| miR-214 | Ovarian Cancer | Transcriptional control (hedgehog signaling) | PTEN | Metastasis, chemoresistance | [129] |
| miR-155 | Cervical Cancer | miRNA sponge, transcriptional control (c-MYB) | SOSC1 | Inflammation | [133] |